The panel / Screening and safety
Sleep screen
Sleep apnoea is the single most consequential thing this panel looks for that is not a blood test. It produces the same symptoms as low testosterone, it lowers testosterone independently of your weight, and it compounds the main risk of the treatment. Missing it is how a man ends up on therapy that makes him worse.
What it measures
A validated questionnaire that estimates your likelihood of obstructive sleep apnoea, covering snoring, witnessed pauses in breathing, daytime tiredness, blood pressure, body size, age, neck circumference and sex. It is a screen, not a diagnosis. A positive screen leads to a sleep study.
We use STOP-BANG rather than the Epworth Sleepiness Scale deliberately. The Epworth measures only how likely you are to doze off, and its sensitivity for apnoea is around 42 to 47 percent, which means it misses more than half. Plenty of men with significant apnoea do not feel especially sleepy.
Why it is on the panel
Because the relationship runs in both directions and the treatment interacts with it. Pooled data across 24 case-control studies found significantly lower testosterone in men with apnoea, driven by intermittent overnight oxygen dips, independent of age and weight. Going the other way, low testosterone promotes the central and airway fat that worsens apnoea. And testosterone therapy raises haematocrit, which untreated apnoea also raises, so the two stack.
Interpretation
Reading the result
The score sorts men into risk bands rather than producing a yes or no.
In that severe obesity cohort, an apnoea-hypopnoea index above 30 independently predicted lower testosterone after adjusting for BMI, diabetes and inflammation. The apnoea was doing work the weight alone did not explain.
What the screen does not tell you
What happens next
A positive screen leads to a sleep study before, not after, any decision about testosterone therapy.
Confirmed apnoea is treated first, because treating it addresses the symptoms, the cardiovascular risk and the haematocrit at once.
Testosterone therapy is approached cautiously where apnoea is untreated, particularly at higher doses, because it can worsen sleep-disordered breathing.
Testosterone is rechecked after apnoea is treated, rather than assumed to be unchanged.